Table 1. Baseline characteristics of included patients.
| No Hospitalization due to decompensation at follow-up N = 287 |
Hospitalization at follow-up due to decompensation N = 51 |
|
|---|---|---|
| Age (years); [SD] | 59.40 [12.09] | 61.45 [10.99] |
| Coffee (cups/day); [SD] | 1.65 [1.65] | 0.47 [0.92] |
| Diabetes (presence); N [%] | 63 [22] | 21 [41] |
| BMI (kg/m2); [SD] | 27.10 [4.95] | 26.20 [5.81] |
| MELD Score; [SD] | 9.68 [3.83] | 13.76 [4.39] |
| Creatinin (mg/dl); [SD] | 0.86 [0.29] | 1.14 [0.83] |
| Albumin (g/dl); [SD] | 4.12 [0.62] | 3.25 [0.59] |
| Bilirubin (mg/dl); [SD] | 1.33 [1.45] | 2.27 [1.68] |
| ALT (U/L); [SD] | 37.59 [43.70] | 34.62 [24.60] |
| yGT (U/L); [SD] | 111.3 [144.82] | 205.66 [296.35] |
| Leukocyte (/nl); [SD] | 6.03 [2.23] | 5.66 [2.74] |
| Hb (mg/dl); [SD] | 13.42 [1.91] | 11.15 [2.31] |
| Platelets (/nl); [SD] | 141.05 [71.21] | 122.96 [78.65] |
| 25(OH)D3 (ng/ml); [SD] | 27.95 [17.81] | 21.24 [18.75] |
| IL-6 (pg/mL); [SD] | 3.61 [4.93] | 1.52 [34.03] |
| I-FABP (pg/mL);[SD] | 1155.5 [928.16] | 1973.2 [2050.9] |
| sCD14 (ng/mL); [SD] | 2.15 [0.66] | 2.58 [0.59] |
| Ascites at baseline, N [%] | 26 [9] | 27 [52] |
| Hepatic encephalopathy at baseline, N [%] | 1 [0.35] | 2 [4] |
| History of ascites, N [%] | 105 [37] | 36 [71] |
| History of hepatic decompensation, N [%] | 13 [45] | 44 [86] |
| Liver cirrhosis etiology of entire cohort n,(%) | ||
| HCV 117 (35) | ||
| HBV 53 (16) | ||
| Alcoholic 103 (30) | ||
| NASH 33 (10) | ||
| Other 32 (11) |
ALT, alanine aminotransferase; BMI, body mass index; range; γGT, γ-glutamyl transferase; Hb, hemoglobin; I-FABP, intestinal fatty acid binding protein; MELD, model of end-stage liver disease.